1. any vaccination/immunization within 30 days before the enrollment. 2. history of covid-19. 3. positive sars-cov-2 screening result obtained by pcr (at screening). 4. test results for igm and igg antibodies to sars-cov-2 is positive. 5. administration of steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment. 6. pregnancy or breast-feeding. 7. acute coronary syndrome or stroke suffered less than one year before the enrollment. 8. tuberculosis, chronic systemic infections in medical history. 9. drug allergy (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study vaccine components, acute exacerbation of allergic diseases on the enrollment day. 10. known allergic reactions to vaccination 11. history of asthma 12. neoplasms in medical history. 13. major operations in the past 12 months before study vaccine administration. this will include but not limited to; major organs transplant, bone marrow donation, etc. 14. splenectomy in the past medical history 15. neutropenia (absolute neutrophil count \<1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin \<80 g/l), immunodeficiency in the medical history within 6 months before the enrollment. 16. any family member with immunodeficiency, cancer, or transplantation 17. the active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis b, or c. 18. subjects with diabetes, heart disease, chronic kidney disease, or dialysis 19. subjects with latent tuberculosis infection 20. anorexia, protein deficiency of any origin. 21. subjects with any metabolic diseases 22. tattoos or scars at the injection site (deltoid muscle area), which in the medical opinion of the investigator does not allow assessing the local response to the study vaccine/placebo administration. 23. alcohol or drug addiction in medical history. 24. participation in any other interventional clinical trial within the previous 90 days (from the administration of the vaccine). 25. any other condition that the study physician considers as a barrier to the trial completion as per the protocol. 26. healthcare workers

1. any vaccination/immunization within 30 days before the enrollment. 2. history of covid-19. 3. positive sars-cov-2 screening result obtained by pcr (at screening). 4. test results for igm and igg antibodies to sars-cov-2 is positive. 5. administration of steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment. 6. pregnancy or breast-feeding. 7. acute coronary syndrome or stroke suffered less than one year before the enrollment. 8. tuberculosis, chronic systemic infections in medical history. 9. drug allergy (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study vaccine components, acute exacerbation of allergic diseases on the enrollment day. 10. known allergic reactions to vaccination 11. history of asthma 12. neoplasms in medical history. 13. major operations in the past 12 months before study vaccine administration. this will include but not limited to; major organs transplant, bone marrow donation, etc. 14. splenectomy in the past medical history 15. neutropenia (absolute neutrophil count \<1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin \<80 g/l), immunodeficiency in the medical history within 6 months before the enrollment. 16. any family member with immunodeficiency, cancer, or transplantation 17. the active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis b, or c. 18. subjects with diabetes, heart disease, chronic kidney disease, or dialysis 19. subjects with latent tuberculosis infection 20. anorexia, protein deficiency of any origin. 21. subjects with any metabolic diseases 22. tattoos or scars at the injection site (deltoid muscle area), which in the medical opinion of the investigator does not allow assessing the local response to the study vaccine/placebo administration. 23. alcohol or drug addiction in medical history. 24. participation in any other interventional clinical trial within the previous 90 days (from the administration of the vaccine). 25. any other condition that the study physician considers as a barrier to the trial completion as per the protocol. 26. healthcare workers

any vaccination/immunization within 30 days before the enrollment. history of covid-19. positive sars-cov-2 screening result obtained by pcr (at screening). test results for igm and igg antibodies to sars-cov-2 is positive. administration of steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment. pregnancy or breast-feeding. acute coronary syndrome or stroke suffered less than one year before the enrollment. tuberculosis, chronic systemic infections in medical history. drug allergy (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study vaccine components, acute exacerbation of allergic diseases on the enrollment day. known allergic reactions to vaccination history of asthma neoplasms in medical history. major operations in the past 12 months before study vaccine administration. this will include but not limited to; major organs transplant, bone marrow donation, etc. splenectomy in the past medical history neutropenia (absolute neutrophil count <1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin <80 g/l), immunodeficiency in the medical history within 6 months before the enrollment. any family member with immunodeficiency, cancer, or transplantation the active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis b, or c. subjects with diabetes, heart disease, chronic kidney disease, or dialysis subjects with latent tuberculosis infection anorexia, protein deficiency of any origin. subjects with any metabolic diseases tattoos or scars at the injection site (deltoid muscle area), which in the medical opinion of the investigator does not allow assessing the local response to the study vaccine/placebo administration. alcohol or drug addiction in medical history. participation in any other interventional clinical trial within the previous 90 days (from the administration of the vaccine). any other condition that the study physician considers as a barrier to the trial completion as per the protocol. healthcare workers

any vaccination/immunization within 30 days before the enrollment. history of covid-19. positive sars-cov-2 screening result obtained by pcr (at screening). test results for igm and igg antibodies to sars-cov-2 is positive. administration of steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment. pregnancy or breast-feeding. acute coronary syndrome or stroke suffered less than one year before the enrollment. tuberculosis, chronic systemic infections in medical history. drug allergy (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study vaccine components, acute exacerbation of allergic diseases on the enrollment day. known allergic reactions to vaccination history of asthma neoplasms in medical history. major operations in the past 12 months before study vaccine administration. this will include but not limited to; major organs transplant, bone marrow donation, etc. splenectomy in the past medical history neutropenia (absolute neutrophil count <1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin <80 g/l), immunodeficiency in the medical history within 6 months before the enrollment. any family member with immunodeficiency, cancer, or transplantation the active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis b, or c. subjects with diabetes, heart disease, chronic kidney disease, or dialysis subjects with latent tuberculosis infection anorexia, protein deficiency of any origin. subjects with any metabolic diseases tattoos or scars at the injection site (deltoid muscle area), which in the medical opinion of the investigator does not allow assessing the local response to the study vaccine/placebo administration. alcohol or drug addiction in medical history. participation in any other interventional clinical trial within the previous 90 days (from the administration of the vaccine). any other condition that the study physician considers as a barrier to the trial completion as per the protocol. healthcare workers

1. any vaccination/immunization within 30 days before the enrollment. 2. history of covid-19. 3. positive sars-cov-2 screening result obtained by pcr (at screening). 4. test results for igm and igg antibodies to sars-cov-2 is positive. 5. administration of steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment. 6. pregnancy or breast-feeding. 7. acute coronary syndrome or stroke suffered less than one year before the enrollment. 8. tuberculosis, chronic systemic infections in medical history. 9. drug allergy (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study vaccine components, acute exacerbation of allergic diseases on the enrollment day. 10. known allergic reactions to vaccination 11. history of asthma 12. neoplasms in medical history. 13. major operations in the past 12 months before study vaccine administration. this will include but not limited to; major organs transplant, bone marrow donation, etc. 14. splenectomy in the past medical history 15. neutropenia (absolute neutrophil count <1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin <80 g/l), immunodeficiency in the medical history within 6 months before the enrollment. 16. any family member with immunodeficiency, cancer, or transplantation 17. the active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis b, or c. 18. subjects with diabetes, heart disease, chronic kidney disease, or dialysis 19. subjects with latent tuberculosis infection 20. anorexia, protein deficiency of any origin. 21. subjects with any metabolic diseases 22. tattoos or scars at the injection site (deltoid muscle area), which in the medical opinion of the investigator does not allow assessing the local response to the study vaccine/placebo administration. 23. alcohol or drug addiction in medical history. 24. participation in any other interventional clinical trial within the previous 90 days (from the administration of the vaccine). 25. any other condition that the study physician considers as a barrier to the trial completion as per the protocol. 26. healthcare workers

1. any vaccination/immunization within 30 days before the enrollment. 2. history of covid-19. 3. positive sars-cov-2 screening result obtained by pcr (at screening). 4. test results for igm and igg antibodies to sars-cov-2 is positive. 5. administration of steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment. 6. pregnancy or breast-feeding. 7. acute coronary syndrome or stroke suffered less than one year before the enrollment. 8. tuberculosis, chronic systemic infections in medical history. 9. drug allergy (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study vaccine components, acute exacerbation of allergic diseases on the enrollment day. 10. known allergic reactions to vaccination 11. history of asthma 12. neoplasms in medical history. 13. major operations in the past 12 months before study vaccine administration. this will include but not limited to; major organs transplant, bone marrow donation, etc. 14. splenectomy in the past medical history 15. neutropenia (absolute neutrophil count <1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin <80 g/l), immunodeficiency in the medical history within 6 months before the enrollment. 16. any family member with immunodeficiency, cancer, or transplantation 17. the active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis b, or c. 18. subjects with diabetes, heart disease, chronic kidney disease, or dialysis 19. subjects with latent tuberculosis infection 20. anorexia, protein deficiency of any origin. 21. subjects with any metabolic diseases 22. tattoos or scars at the injection site (deltoid muscle area), which in the medical opinion of the investigator does not allow assessing the local response to the study vaccine/placebo administration. 23. alcohol or drug addiction in medical history. 24. participation in any other interventional clinical trial within the previous 90 days (from the administration of the vaccine). 25. any other condition that the study physician considers as a barrier to the trial completion as per the protocol. 26. healthcare workers